Proteins linked to ALS and dementia may also govern DNA mismatch repair
New findings from Houston Methodist reveal that a protein associated with neurodegenerative diseases such as dementia and amyotrophic lateral sclerosis (ALS) also influences DNA mismatch repair, a crucial system that ensures accurate DNA replication and cell health. This insight could reshape how scientists view both cancer and neurodegenerative disorders.
In the study published in Nucleic Acids Research, researchers show that the protein TDP-43 governs genes involved in fixing DNA mistakes. When TDP-43 is either reduced or overproduced, these repair genes become overactive, damaging neurons and destabilizing the genome, thereby potentially fueling cancer development.
"DNA repair is among the most fundamental processes in biology," said Muralidhar L. Hegde, Ph.D., a professor of neurosurgery at the Houston Methodist Research Institute’s Center for Neuroregeneration. "Our work demonstrates that TDP-43 is not merely another RNA-binding protein tied to splicing, but a pivotal regulator of the mismatch repair machinery. This has major implications for diseases like ALS and frontotemporal dementia (FTD) where this protein malfunctions."
The researchers also identified a link between TDP-43 and cancer. Analyses of large cancer datasets indicated that high levels of the protein correlate with higher mutation rates.
"This suggests the biology of this protein extends beyond ALS and FTD," Hegde noted. "In cancers, TDP-43 appears to be upregulated and associated with an increased mutation burden, placing it at the crossroads of two of today’s most critical disease domains: neurodegeneration and cancer."
Related discoveries and implications
- The new research points to potential therapeutic strategies by moderating overactive DNA repair in laboratory models, partially reversing damage linked to TDP-43 dysfunction.
- Controlling DNA mismatch repair could emerge as a viable approach for treating related neurodegenerative conditions.
Collaborators on the project include researchers from Houston Methodist, MD Anderson Cancer Center, the University of Massachusetts, UT Southwestern Medical Center, and Binghamton University.
Funding and support came mainly from the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIH), along with the Sherman Foundation Parkinson's Disease Research Challenge Fund and internal Houston Methodist Research Institute funds.
Note on context
This summary draws from the journal publication and affiliated press materials. Readers should consult medical professionals for medical advice and verify data with the original sources when making health-related decisions.
Would this finding change how you think about the relationship between neurodegeneration and cancer, or raise new questions about potential treatments? Share your thoughts in the comments.
